Antiepileptic Drugs, Cognition and Neurodevelopment

  • MJ Eadie
  • FJE Vajda


Antiepileptic drug exposure in utero may have adverse effects on the developing brain, as has been shown in experimental animals. Exposure in the first trimester of human pregnancy may be associated with the occurrence of physical malformations in the foetus but, in addition, foetal valproate exposure poses a significant risk for the cognitive development of the infant, an effect that is dose dependent. Carbamazepine and lamotrigine exposures appear to hold a lesser risk for cognitive development, while the risks associated with exposure to the other antiepileptic drugs are uncertain. Further, evidence has become available that intrauterine valproate exposure may be associated with the development of autism-spectrum disorder in childhood. Not enough data exists to clarify the situation in this regard for the other antiepileptic drugs.


Status Epilepticus Antiepileptic Drug Foetal Exposure Language Score Valproate Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Adab N, Kini U, Vinten J et al (2004) The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 75:1575–1583PubMedCentralCrossRefPubMedGoogle Scholar
  2. Asimiadou S, Bittigau P, Felderhoff-Mueser U et al (2005) Protection with estradiol in developmental models of apoptotic neurodegeneration. Ann Neurol 58:266–276CrossRefPubMedGoogle Scholar
  3. Baker GA, Bromley RL, Brigg SM et al (2015) IQ at 6 years after in utero exposure to antiepileptic drugs. A controlled cohort study. Neurology 84:382–390PubMedCentralCrossRefPubMedGoogle Scholar
  4. Bergman A, Feigenbaum JJ, Yanai J (1982) Neuronal losses in mice following both prenatal and neonatal exposure to phenobarbital. Acta Anat 114:185–192CrossRefPubMedGoogle Scholar
  5. Bittigau P, Sifringer M, Genz K et al (2002) Aeds and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci U S A 99:15089–15094PubMedCentralCrossRefPubMedGoogle Scholar
  6. Bittigau P, Sifringer M, Ikonomidou C (2003) Antiepileptic drugs and apoptosis. Ann NY Acad Sci 993:103–114CrossRefPubMedGoogle Scholar
  7. Blom HJ, Shaw GM, den Heijer MS, Finnell RH (2006) Neural tube defects and folate; case far from closed. Nat Rev Neurosci 7:724–731PubMedCentralCrossRefPubMedGoogle Scholar
  8. Bolanos AR, Sarkisian M, Yang Y et al (1998) Comparison of valproate and phenobarbital treatment after status epilepticus in rats. Neurology 51:41–48CrossRefPubMedGoogle Scholar
  9. Bromley RL, Mawer G, Clayton-Smith J, Baker GA, Liverpool and Manchester Neurodevelopment Group (2008) Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 71:1923–1924CrossRefPubMedGoogle Scholar
  10. Christianson AL, Chesler N, Kromberg JG (1994) Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. Dev Med Child Neurol 36:361–369CrossRefPubMedGoogle Scholar
  11. Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J (2011) Neurodevelopment of children exposed to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child 96:643–647CrossRefPubMedGoogle Scholar
  12. Deblay MF, Vert P. André M (1982) Children of epileptic mothers. Nouv Presse Med 11: 173–176Google Scholar
  13. Delgado-Escueta AV, Janz D (1992) Consensus guidelines: preconception counselling, management, and care of the pregnant woman with epilepsy. Neurology 42(4 Suppl 5):149–160PubMedGoogle Scholar
  14. Diaz J, Schain RJ (1978) Phenobarbital: effects of long-term administration on behavior and brain of artificially reared rats. Science 199:90–91CrossRefPubMedGoogle Scholar
  15. Dodrill CB, Wilensky AJ (1992) Neuropsychological abilities before and after 5 years of stable antiepileptic drug therapy. Epilepsia 33:327–334CrossRefPubMedGoogle Scholar
  16. Downing C, Biers J, Larson C et al (2010) Genetic and maternal effects on valproic acid teratogeness in C57BL/6J and DBA/2J mice. Toxicol Sci 116:632–639PubMedCentralCrossRefPubMedGoogle Scholar
  17. Eriksson K, Viinikainen K, Mönkkönen A, Aikiä M, Nieminen P, Heinonen S, Kälviäinen R (2005) Children exposed to valproate in utero – population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res 65:189–200CrossRefPubMedGoogle Scholar
  18. Farwell JR, Lee YJ, Hirtz DG, Sulzbacher SI, Ellenberg JH, Nelson KB (1990) Phenobarbital for febrile seizures – effects on intelligence and on seizure recurrence. N Engl J Med 322:364–369. Erratum in: N Engl J Med (1992); 326:144CrossRefPubMedGoogle Scholar
  19. Fishman RH, Ornoy A, Yanai J (1983) Ultrastructural evidence of long-lasting cerebellar degeneration after early exposure to phenobarbital in mice. Exp Neurol 79:212–222CrossRefPubMedGoogle Scholar
  20. Gaily E, Kantola-Sorsa F, Granstrom MI (1988) Intelligence of children of epileptic mothers. J Pediatr 113:677–684CrossRefPubMedGoogle Scholar
  21. Gaily EK, Granström ML, Hiilesmaa VK, Bardy AH (1990) Head circumference in children of epileptic mothers: contributions of drug exposure and genetic background. Epilepsy Res 5:217–222CrossRefPubMedGoogle Scholar
  22. Gaily E, Kantola-Sorsa F, Hiilesmaa V et al (2004) Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 62:28–32CrossRefPubMedGoogle Scholar
  23. Gedzelman E, Meador KJ (2012) Aeds in women with epilepsy during pregnancy. Ther Adv Drug Saf 3:71–87PubMedCentralCrossRefPubMedGoogle Scholar
  24. Glier C, Dzietko M, Bittigau P, Jarosz B, Korobowicz E, Ikonomidou C (2004) Therapeutic doses of topiramate are not toxic to the developing rat brain. Exp Neurol 187:403–409CrossRefPubMedGoogle Scholar
  25. Hanson JW, Myrianthopoulos NC, Harvey MA, Smith DW (1976) Risk to the offspring of women treated with hydantoin anticonvulsants, with emphasis on fetal hydantoin syndrome. J Pediatr 89:662–668CrossRefPubMedGoogle Scholar
  26. Hiilesmaa V (1996) Effects of maternal seizures on the fetus. In: Tomson T, Gram L, Sillanpaa M, Johanessen S (eds) Epilepsy and pregnancy. Wrightson Biomedical Publishing, Peterfield, pp 135–141Google Scholar
  27. Holmes LB, Rosenberger PB, Harvey EA, Khoshbin S, Ryan L (2000) Intelligence and physical features of children of women with epilepsy. Teratology 61:196–202CrossRefPubMedGoogle Scholar
  28. Ikonomidou C, Turski L (2010) Aeds and brain development. Epilepsy Res 88:11–22CrossRefPubMedGoogle Scholar
  29. Ikonomidou C, Scheer I, Wilhelm T et al (2007) Brain morphology alterations in the basal ganglia and the hypothalamus following prenatal exposure to antiepileptic drugs. Eur J Paediatr Neurol 11:297–301CrossRefPubMedGoogle Scholar
  30. Kaindl AM, Asimiadou S, Manthey D, Hagen MV, Turski L, Ikonomidou C (2006) Aeds and the developing brain. Cell Mol Life Sci 63:399–413CrossRefPubMedGoogle Scholar
  31. Katz I, Kim J, Gale K, Kondratyev A (2007) Effects of lamotrigine alone and in combination with MK-801, phenobarbital, of phenytoin on cell death in the neonatal rat brain. J Pharmacol Exp Ther 322:494–500CrossRefPubMedGoogle Scholar
  32. Kaufman AS (1990) Assessing adolescent and adult intelligence. Allyn & Bacon, BostonGoogle Scholar
  33. Kim J, Kondratyev A, Gale K (2007) Antiepileptic drug-induced neuronal cell death in the immature brain: effects of carbamazepine, topiramate, and levetiracetam as monotherapy versus polytherapy. J Pharmacol Exp Ther 323:165–173CrossRefPubMedGoogle Scholar
  34. Loring DW, Meador KJ (2001) Cognitive and behavioral effects of epilepsy treatment. Epilepsia 42(Suppl 8):24–32CrossRefPubMedGoogle Scholar
  35. Majewski F, Steger M, Richter B, Gill J, Rabe F (1981) The teratogenicity of hydantoins and barbiturates in humans, with considerations on the etiology of malformations and cerebral disturbances in the children of epileptic parents. Int J Biol Res Pregnancy 2:37–45PubMedGoogle Scholar
  36. Manthey D, Asimiadou S, Stefovska V et al (2005) Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. Exp Neurol 193:497–503CrossRefPubMedGoogle Scholar
  37. Meador KJ (2005) Cognitive effects of epilepsy and of antiepileptic medications. In: Wyllie E (ed) The treatment of epilepsy. Principles and practices, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1185–1195Google Scholar
  38. Meador KJ, Gilliam FG, Kanner AM, Pellock JM (2001) Cognitive and behavioral effects of antiepileptic drugs. Epilepsy Behav 2:SS1–SS17PubMedGoogle Scholar
  39. Meador KJ, Baker G, Cohen MJ, Gaily E, Westerveld M (2007) Cognitive/behavioral teratogenetic effects of antiepileptic drugs. Epilepsy Behav 11:292–302PubMedCentralCrossRefPubMedGoogle Scholar
  40. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C (2008) Pregnancy outcomes in women with epilepsy: a systematic review and analysis of published pregnancy registers and cohorts. Epilepsy Res 81:1–13PubMedCentralCrossRefPubMedGoogle Scholar
  41. Meador KJ, Baker GA, Browning N et al (2009) Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 360:1597–1605PubMedCentralCrossRefPubMedGoogle Scholar
  42. Meador KJ, Baker GA, Browning N et al (2013) Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 12:244–252PubMedCentralCrossRefPubMedGoogle Scholar
  43. Mikati MA, Holmes GL, Chronopoulos A et al (1994) Phenobarbital modifies seizure-related brain injury in the developing brain. Ann Neurol 36:425–433CrossRefPubMedGoogle Scholar
  44. Molgaard-Nielsen D, Hviid A (2011) Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 305:1996–2002CrossRefPubMedGoogle Scholar
  45. Moore SJ, Turnpenny P, Quinn A, Glover S, Lloyd DJ, Montgomery T, Dean JC (2000) A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 37:489–497PubMedCentralCrossRefPubMedGoogle Scholar
  46. Nadebaum C, Anderson V, Vajda F, Reutens D, Barton S, Wood A (2011a) The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc 17:133–142CrossRefPubMedGoogle Scholar
  47. Nadebaum C, Anderson VA, Vajda F, Reutens DC, Barton S, Wood AG (2011b) Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology 76:719–726CrossRefPubMedGoogle Scholar
  48. Nicolai J, Vles JSH, Aldenkamp AP (2008) Neurodevelopmental delay in children exposed to antiepileptic drugs in utero: a critical review directed at structural study basis. J Neurol Sci 271:1–14CrossRefPubMedGoogle Scholar
  49. Palac S, Meador KJ (2011) Aeds and neurodevelopment: an update. Curr Neurol Neurosci Rep 11:423–427CrossRefPubMedGoogle Scholar
  50. Pulliainen V, Jokelainen M (1994) Effects of phenytoin and carbamazepine on cognitive functions in newly diagnosed epileptic patients. Acta Neurol Scand 89:81–86CrossRefPubMedGoogle Scholar
  51. Pulliainen V, Jokelainen M (1995) Comparing the cognitive effects of phenytoin and carbamazepine in long-term monotherapy: a two-year follow-up. Epilepsia 36:1195–1202CrossRefPubMedGoogle Scholar
  52. Rasalam AD, Hailey H, Williams JH, Moore SJ, Turnpenny PD, Lloyd DJ, Dean JC (2005) Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol 47:551–555CrossRefPubMedGoogle Scholar
  53. Reinisch JM, Sanders SA, Mortensen EL, Rubin DB (1995) In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 274:1518–1525CrossRefPubMedGoogle Scholar
  54. Rogel-Fuchs Y, Newman ME, Trombka D, Zahalka EA, Yanai J (1992) Hippocampal cholinergic alterations and related behavioral deficits after early exposure to phenobarbital. Brain Res Bull 29:1–6CrossRefPubMedGoogle Scholar
  55. Sattler JM (1992) Assessment of children’s intelligence and special abilities. Allyn & Bacon, BostonGoogle Scholar
  56. Schain RJ, Watanabe K (1975) Effect of chronic phenobarbital administration upon brain growth of the infant rat. Exp Neurol 47:509–515CrossRefPubMedGoogle Scholar
  57. Scolnik D, Nulman I, Rovet J et al (1994) Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 271:767–770. Erratum in JAMA (1994); 271:1745CrossRefPubMedGoogle Scholar
  58. Shallcross R, Bromley RL, Irwin B et al (2011) Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 76:383–389PubMedCentralCrossRefPubMedGoogle Scholar
  59. Smith DB, Craft BR, Collins J et al (1986) Behavioral characteristics of epilepsy patients compared with normal controls. Epilepsia 27:760–768CrossRefPubMedGoogle Scholar
  60. Smith KR Jr, Goulding PM, Wilderman D et al (1994) Neurobehavioral effects of phenytoin and carbamazepine in patients recovering from brain trauma: a comparative study. Arch Neurol 51:653–660CrossRefPubMedGoogle Scholar
  61. Stefovska VG, Uckermann O, Czuczwar M et al (2008) Sedative and anticonvulsant drugs suppress postnatal neurogenesis. Ann Neurol 64:434–445CrossRefPubMedGoogle Scholar
  62. Tomson T, Klein P (2015) Fine-tuning risk assessment with antiepileptic drug use in pregnancy. Neurology 84:339–340CrossRefPubMedGoogle Scholar
  63. Vajda FJE, O’Brien T, Hitchcock A, Graham J, Lander C, Eadie M (2007) The Australian antiepileptic drug in pregnancy register: aspects of data collection and analysis. J Clin Neurosci 14:936–942CrossRefPubMedGoogle Scholar
  64. Vajda FJE, O’Brien TJ, Lander CM, Graham J, Eadie MJ (2014) The teratogenicity of the newer antiepileptic drugs – an update. Acta Neurol Scand 130:234–238CrossRefPubMedGoogle Scholar
  65. Vanoverloop D, Schnell RR, Harvey EA, Holmes LB (1992) The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age. Neurotoxicol Teratol 14:329–335CrossRefPubMedGoogle Scholar
  66. Wide K, Henning E, Tomson T, Winbladh B (2002) Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatr 91:409–414CrossRefPubMedGoogle Scholar
  67. Williams G, King J, Cunningham M, Stephan M, Kerr B, Hersh JH (2001) Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol 43:202–206CrossRefPubMedGoogle Scholar
  68. Wood AG, Chen J, Barton S et al (2014) Altered cortical thickness following prenatal sodium valproate exposure. Ann Clin Transl Neurol 1:497–501PubMedCentralCrossRefPubMedGoogle Scholar
  69. Wood AG, Nadebaum C, Anderson VA, Reutens DC, Barton S, O’Brien TJ, Vajda FJE (2015) Prospective assessment of autism traits in children exposed to antiepileptic drugs during pregnancy. Epilepsia 56:1047–1055 Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • MJ Eadie
    • 1
  • FJE Vajda
    • 2
  1. 1.Clinical Neurology and NeuropharmacologyUniversity of Queensland, and Honorary Consultant Neurologist, Royal Brisbane and Women’s HospitalBrisbaneAustralia
  2. 2.Department of Medicine and Neurology Director of the Australian Epilepsy and Pregnancy RegisterUniversity of Melbourne and Royal Melbourne HospitalMelbourneAustralia

Personalised recommendations